SCHEMBL2573591

SCHEMBL2573591

Cc1cc(S(C)(=O)=O)ccc1-c1cccc2nc(Nc3ccc(C(=O)N(C)C)cc3)oc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 9/20 0.54
JAK1 P23458 8/20 0.54
TYK2 P29597 7/20 0.54
JAK3 P52333 7/20 0.54
KDM1A O60341 1/20 0.52
RPS6KA2 Q15349 4/20 0.40
PTK2 Q05397 1/20 0.40
USP2 O75604 3/20 0.40
LMNA P02545 3/20 0.40
TP53 P04637 3/20 0.40
CYP1A2 P05177 3/20 0.40
CYP3A4 P08684 3/20 0.40
CYP2C19 P33261 3/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
TSHR P16473 2/20 0.40
MAPK1 P28482 2/20 0.40
KDM4E B2RXH2 2/20 0.40
HPGD P15428 2/20 0.40
HSD17B10 Q99714 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2569572 0.80 JAK2 (0.66) JAK2JAK1TYK2JAK3KDM1A
SCHEMBL2573586 0.77 JAK2 (0.64) JAK2JAK1TYK2JAK3KDM1A
SCHEMBL2573648 0.76 JAK1 (0.58) JAK2JAK1TYK2JAK3RPS6KA2
SCHEMBL2573631 0.72 JAK1 (0.57) JAK2JAK1TYK2JAK3RPS6KA2
SCHEMBL2573555 0.71 JAK2 (0.60) JAK2JAK1TYK2JAK3RPS6KA2
SCHEMBL2571023 0.70 JAK1 (0.72) JAK2JAK1TYK2JAK3RPS6KA2
SCHEMBL2573741 0.68 JAK1 (0.80) JAK2JAK1TYK2JAK3RPS6KA2
SCHEMBL12172231 0.67 JAK1 (0.67) JAK2JAK1TYK2JAK3RPS6KA2
SCHEMBL12172200 0.67 JAK1 (0.64) JAK2JAK1TYK2JAK3RPS6KA2
SCHEMBL2573697 0.67 JAK1 (1.00) JAK2JAK1TYK2JAK3HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629168-B2 Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors NOVARTIS AG (CH) 2014-01-14 US claimed
EP-2066647-B1 BENZOXAZOLES AND OXAZOLOPYRIDINES BEING USEFUL AS JANUS KINASES INHIBITORS NOVARTIS AG (CH) 2011-11-09 EP claimed
US-20100009978-A1 Benzoxazoles and Oxazolopyridines Being Useful as Janus Kinases Inhibitors NOVARTIS AG 2010-01-14 US claimed
EP-2066647-A1 BENZOXAZOLES AND OXAZOLOPYRIDINES BEING USEFUL AS JANUS KINASES INHIBITORS Novartis AG (CH) 2009-06-10 EP claimed
WO-2008031594-A1 BENZOXAZOLES AND OXAZOLOPYRIDINES BEING USEFUL AS JANUS KINASES INHIBITORS NOVARTIS AG (CH) 2008-03-20 WO claimed
US-8629168-B2 Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors NOVARTIS AG (CH) 2014-01-14 US disclosed
EP-2066647-B1 BENZOXAZOLES AND OXAZOLOPYRIDINES BEING USEFUL AS JANUS KINASES INHIBITORS NOVARTIS AG (CH) 2011-11-09 EP disclosed
US-20100009978-A1 Benzoxazoles and Oxazolopyridines Being Useful as Janus Kinases Inhibitors NOVARTIS AG 2010-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009978-A1 Benzoxazoles and Oxazolopyridines Being Useful as Janus Kinases Inhibitors JAK2, JAK3, JAK1 JAK2 1/4885JAK1 3/4885TYK2 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.